These projects all focus on improving treatments for prostate cancer. This includes research into new treatment options, but also work that aims to improve treatments that we already have. Ultimately, we want to find ways to target treatments so that men get the best treatments for their particular circumstances.
Dr Sharp aims to identify proteins that bind to altered versions of the androgen receptor, and investigate whether blocking their activity can hinder cancer progression.
By assessing how tumour cells repair their DNA, Dr Mateo aims to develop a tool that can identify those patients with a poor prognosis who may benefit from a new treatment.
Funded research by Dr Rich Williams of Queen's University Belfast into how inhibiting Legumain may improve prognosis.
Funded research by Dr Wafa Al-Jamal of the University of East Anglia into ways of targeting chemotherapy drugs directly to cancerous cells.
Funded research by Prof. Charlotte Bevan of Imperial College London into creating a new treatment strategy for advanced prostate cancer by manipulating prohibitin.
Funded research by Dr Matthew David Lloyd of Bath University into whether manipulating the AMACR protein can help prevent drug resistance.
Funded research by Prof. Kevin Prise of Queen's University Belfast into improving existing radiotherapy treatments using drugs that prevent DNA repair.
Funded research by Prof. Iain McEwan of Aberdeen University into whether blocking the androgen receptor protein can improve the effectiveness of hormone therapy.
Funded research by Dr. Christine Galustian of King's College London into enabling immune system therapy proteins to stay at the site of tumours rather than circulate.
Funded research by Prof. Gary Cook of St Thomas' Hospital, London into the use of 99mTc maraciclatide SPECT imaging to detect and measure the treatment response of bone metastases.
Funded research by Dr Sophie Papa of King's College London into whether the protein drug FAB4 could guide certain immune white blood cells to migrate into and attack prostate cancer.
Funded research by Dr Marco Gerlinger of Barts Cancer institute into whether targeting circulating tumour DNA can give a better picture of individual treatment response and suitability.
Funded research by Dr. Anne Collins of York University into the effect of blocking the stat3 protein in cells from men with prostate cancer rather than lab-grown cells.
Funded research by Dr Declan McKenna of Ulster University into combining a bioreductive drug with a commonly used treatment to kill hypoxic tumour cells.
Funded research by Dr Simon Crabb of Southampton University into using the enzyme LSD1 to inhibit the growth of prostate cancer cells by suppressing androgen receptors.
Funded research by Dr Rob Mairs of Glasgow University into using the radiopharmaceutical 131I-Trofex to selectively deliver radiation to cancerous sites.
Funded research by Professor Colin Cooper of the University of East Anglia into a new therapy that uses nanoparticles containing SK1 inhibitors together with docetaxel chemotherapy.
Funded research by Professor Marco Falasca of Queen Mary University of London into drugs to block two newly-identified molecules important for the growth of prostate cancer cells.
Funded research by Professor Simon Mackay of SIPBS into the effect of a particular protein associated with advanced prostate cancer, and the refinement of two drug-like compounds designed to prevent its action.
Funded research by Dr Gunnell Hallden of Queen Mary University of London into using a modified virus in combination with chemotherapy to kill cancer cells.
Funded research by Dr. Charlotte Bevan of Imperial College London into a newly-designed androgen receptor inhibitor and a targeted method for delivering it, optimising a drug that works when cancer has become less receptive to treatment.
Funded research by Dr Mark Coles of York University into the stroma cells that surround tumours, what happens to them during tumour spread, and whether affecting them can provide a means of preventing metastasis.
Funded research by Dr Deborah Enting of King's College London into how the NKG2D receptor, which is found on the body's own immune cells and binds specifically to cancer cells, can be used to fight cancer.
Funded research by Dr Helen McCarthy of Queen's University, Belfast into a peptide-protected DNA vaccine that stimulates an immune response to cancer cells.
Funded Research by Dr Matthew David Lloyd of University of Bath to discover new drugs to specifically block the function of a protein called AMACR, which is involved in prostate cancer growth
Funded research by Professor Hardev Pandha of the University of Surrey which will look at combining the reovirus with other drugs called checkpoint blockers to treat prostate cancer.
Funded research by Ms Ashley d'Aquino of the Royal Marsden Hospital into developing new radiotherapy techniques using 3D scanning, with the aim of better customising dosages and reducing side effects.
Funded research by Dr Joanne Edwards of Glasgow University into new ways to treat advanced prostate cancer after hormone therapy stops working.
Funded research by Dr Jonathan Coulter of Queens University Belfast investigating the use of a reactive oxygen species to damage the cancer cell membrane.
Funded research by Dr Ananya Choudhury of the University of Manchester which looks to identify patients with low oxygen (hypoxic) prostate cancers. This will allow doctors to select patients who are most likely to benefit from appropriate radiotherapy.
Funded research by Dr Dow-Mu Koh of Royal Marsden Hospital which looks to test whether a technique called whole body diffusion weighted imaging is a reliable method of how well patients with advanced prostate cancer, who have been treated with olaparib, are responding to treatment.
Funded research by Professor Hing Leung of the University of Glasgow which looks at whether adding statins to hormone treatment will improve treatment response in hormone resistant disease, and whether any new tests can track how well the cancer is responding to treatment.
Funded research by Dr Andrew Chantry and Jessica Watt of the University of East Anglia into new ways to prevent the growth of prostate cancer.
Funded research by Prof Michael Threadgill of the University of Bath into developing an advanced drug delivery system to kill prostate cancer cells.
Dr Clarkson and his team will test the ability of a new drug developed in their lab to kill prostate cancer stem cells. Dr Clarkson believes that these are the cells responsible for driving cancer spread even after surgery or radiotherapy in men with high-risk localised prostate cancers.
This project aims to develop and test a brand new class of drug that works by disrupting the genetic instructions produced by a cancer promoting gene that’s inappropriately activated in over 50 per cent of prostate cancers.
Dr Zwacka and his team will look into how well, and how safely, a cancer-killing protein loaded into adult stem cells can infiltrate and kill prostate cancer cells in the main prostate tumour and elsewhere in the body.
This project looks into how patients respond to therapy with the aim of matching each individual patient to the best available treatment.
This team will investigate a potential new treatment for men with a mutation in a gene called PTEN, which is common in hormone resistant advanced prostate cancer.
This project looks to develop a tool to work out which men need additional radiotherapy treatment for cancer that has spread outside the prostate to the pelvic lymph nodes.
Our first Travelling Prize Fellow will be working with a team in Rotterdam to develop the skills to further develop promising drugs for treating prostate cancer.
We are funding Professor de Bono and his team to develop a simple genetic test to work out which men have this mutation. This will help them to give a more accurate prognosis to men with this mutation and to recruit them for a bigger clinical trial of olaparib.
Dr Tierney and her colleagues will review data from clinical trials worldwide in new and different ways. This will help them to work out which are the best current treatments for advanced prostate cancer as quickly as possible, and identify clinical measurements that predict treatment success to try to speed up future trials.
The researchers have already designed and validated key components of a vaccine to treat and prevent prostate cancer. In this project, they will put all the parts together and test them to make the vaccine as effective as possible.